Solutions

Wir haben für alles eine Lösung – und die entsprechende Erfahrung. In unseren derzeit sieben Kompetenzbereichen stehen wir Ihnen mit unserem umfassenden Know-how mit Rat und Tat zur Seite.

Alle Solutions

Willkommen in unserem virtuellen Showroom!

In unserem virtuellen Showroom präsentieren wir Ihnen unser umfangreiches Portfolio und Innovationen – rund um die Uhr!

Software

Software

Mit unseren Werum PAS-X Softwarelösungen sind wir weltweit führender Anbieter und Partner für die Pharma-, Biotech- und Zell- und Gentherapie-Industrie. Durch unsere PAS-X MES Suite und weitere intelligente Produkte und Services erschließen Sie das volle Potenzial ihrer Wertschöpfungsketten.

Übersicht Software

Transportsysteme

Transportsysteme

Wir sind Spezialisten für komplette Transportsysteme im Bereich Pharma- und Medizinprodukte. Unsere Lösungen sind maßgebend im Bereich des kontaktlosen und sicheren Transports von z.B. Glasspritzen.

Übersicht Transportsysteme

Inspektion

Inspektion

Als weltweit führender Inspektionsexperte entwicklen wir Lösungen für die Pharma und Biotechindustrie. Unser Angebot reicht von Hochleistungsmaschinen und Halbautomaten über Laboreinheiten bis Inspektionsapplikationen für die Inprozesskontrolle.

Übersicht Inspektion

Maschinen-Finder

Verpackungsmaterial

Verpackungsmaterial

Als langjährige Spezialisten entwickeln wir Verpackungslösungen für innovative und hochwertige Pharma-Sekundärverpackungen aus Karton. Wir bieten Ihnen Lösungen für Fälschungssicherheit, Standard- Faltschachteln und vieles mehr.

Übersicht Verpackungsmaterial

Services

Sie benötigen Hilfe bei einem bestimmten Produkt oder haben Fragen zu einem unserer Kompetenzbereiche? Nutzen Sie unser umfangreiches Serviceangebot, wir unterstützen Sie schnell und unkompliziert.

Alle Services

Transportsysteme

Transportsysteme

Wir sind Spezialisten für komplette Transportsysteme im Bereich Pharma- und Medizinprodukte. Unsere Lösungen sind maßgebend im Bereich des kontaktlosen und sicheren Transports von z.B. Glasspritzen.

Übersicht Transportsysteme Services

Inspektion

Inspektion

Wir bieten unseren Kunden vielfältige Inspektionslösungen und Qualitätskontrollen auf höchstem Niveau. Erfahren Sie mehr über die passende Technologie für Ihre Anforderungen.

Übersicht Inspektion Services

Verpackungsmaschinen

Verpackungsmaschinen

Unsere Verpackungsmaschinen sichern Ihnen maximale Flexibilität und Produktivität für Ihre Verpackungsprozesse. Erfahren Sie mehr über unsere modularen, kundenspezifischen Verpackungslösungen.

Übersicht Verpackungsmaschinen Services

Support whenever and whereever you need it. Reduce your downtime and improve your production quality with Körber Xpert View.

Verpackungsmaterial

Verpackungsmaterial

Die Anforderungen an Arzneimittelverpackungen sind hoch: Fälschungs- und kindersicher sollen sie sein, aber auch kompakt und nachhaltig. Erfahren Sie hier, wie wir Verpackungen zukunftssicher machen.

Übersicht Verpackungsmaterial Services

Über uns

Wir von Körber im Geschäftsfeld Pharma sind der Ansprechpartner, wenn es um pharmazeutische Produkte geht. Als führender Systemanbieter beraten wir unsere Kunden von der Entwicklung über die Herstellung bis zur Inspektion und Verpackung ihrer Produkte.

Alles über uns

Mediacenter

Mediacenter

In unserem Mediacenter finden Sie alle Inhalte rund um unsere Webinare, Produkt- und Markeninformationen wie Downloads, Videos und dem Virtuelen Showroom gesammelt an einem Ort.

Alle Medienangebote

Referenzen

Referenzen

Sie möchten wissen, wie wir unterschiedliche Kundenanforderungen nachhaltig und effizient gelöst haben? 
Was Projektpartner über uns sagen oder mit welchen Branchenauszeichnungen unsere Innovationen ausgezeichnet wurden? 

Thomas Zahel

Blog

Pharma Software: How to perform successful process characterization

This expert article provides insights on how statistical tools and software tailored to pharmaceutical needs can be applied to show the required confidence that the design of the manufacturing process is well understood, controlled and ready for routine production. Learn about key indicators for successful process characterization and win valuable insights about the 7 steps to follow from the initial process validation master plan to the final establishment of a holistic control strategy. 

Your Key Take-Aways:

Process Characterization (PC) - also called process validation stage 1 (PV) - is the process of showing regulatory authorities the capability of consistently delivering product quality.     Moreover, it is a regulatory requirement to achieve licensure of a pharmaceutical product (read our blog post What is Process Characterization? to explore further details on the regulatory background).

Failing to efficiently plan and execute activities on that first stage leads to increased time-to-market. Typical goals of a Process Characterization Strategy (PCS) focus on identifying process parameters that have an impact on product quality and yield, for example:

  • Identify interactions between process parameters and critical quality attributes
  • Justify and - if necessary - adjust manufacturing operating ranges and acceptance criteria
  • Ensure that the process delivers a product with reproducible yields and purity

Successful PC is achieved when:

  • Scope, deliverables, and timelines are well aligned between all stakeholders
  • Evidence-based decision making is increased and influence of the loudest voice during risk assessments is reduced
  • Potential offsets between scales are being identified
  • Impact of process parameters (PP) on critical quality attributes (CQA) is identified at minimal experimental effort
  • A model-based control strategy is established for each unit operation
  • A holistic control strategy, taking the mutual interplay of all unit operations into account, is achieved using integrated process modeling. This shows that the manufacturing process is well understood and consistently delivers the highest product quality in drug substance.
    

1. Achieve project transparency with a Process Validation Master Plan 

You should start with a plan comprising all intended steps and goals. Data collection and evaluation need to be aligned as usually many internal stakeholders (process development, manufacturing, and manufacturing science departments) and external like CRO & CMO are involved. Transparent information about timelines, data flows, interfaces to departments/ stakeholders and deliverables guarantee timely delivery of the final PCS report and allows to include it into BLA filing.

With PAS-X CMC Consulting, Körber supports in the development of requirements for each task and herein delivers a detailed timeline that ensures timely delivery of regulatory documents and finish process characterization studies.

    

2. Avoid unpleasant side effects and conduct a risk assessment

The aim of a Failure Mode and Effects Analysis (FMEA) is to pre-select potential impacting factors for further experimental investigation and rate other factors as being not critical based on process expertise. It is very important to incorporate data-based prior information of occurrences and severities. By that, you reduce the impact of individual opinions on the final FMEA outcome. 

Our PAS-X CMC Consulting experts assist in regulatory compliant qualitative and quantitative risk analysis according to ICH Q9. 

3. Start investigating impurity clearance

Focus on the important unit operations that ensure reaching the quality target product profile for each critical quality attribute. Thereby, you can minimize the experimental and analytical effort as you do not have to investigate all your CQAs at each intermediate step in your manufacturing process. 

A biopharmaceutical process can be compared to a car: If we exchange the engine of a trashy vehicle, it will not run faster when it still has no tires. Therefore, it is important to understand which part (here unit operations) needs to be improved to consistently deliver product quality. This can only be answered when looking and modeling the entire process. 

Already at this point we can use the integrated process model to decide if we should invest into a run of a spiking study showing increased downstream capability or rather running an additional Design of experiments (DoE) run in upstream. Without this knowledge the wrong or too many runs are planned which is a cost driver in PC projects. 

4. Detect offsets between scales and perform SDM Qualification

Adapting a control strategy for large sale, scale down models (SDM) need to be established (ICH Q8). To achieve this, you should apply good industry standards to keep scale independent factors constant between the scales. 

Additionally, data must be provided to show that the performance of the scales is comparable, and offsets can be considered. Usually this is done using equivalence testing with a two-one-sided t-test (TOST). A cost-efficient alternative is to analyze scale runs together with DoE experiments and estimate the scale offsets from this analysis. This will also provide a good overview about possible differences in variance between the scales. 

5. Experiment and evaluate to gain knowledge fast

Generously invest time and energy into planning experiments as this is the key to efficiently generating knowledge. Experimental criticality assessment is a central point to understand the impact of PPs on CQAs and thereby are of utmost importance to setting the right control strategy.

DoE are more statistically powerful than one factor at a time (OFAT) experiments with a smaller number of runs. Statistical power of an experiment shows you the likelihood to increase your process knowledge by conducting the planned trials. 

This can be visualized by looking at the screening space you cover when conducting an OFAT vs. a DoE. With the same number of experiments, DoEs can cover a much large space in your screening space:

You might argue that this will not work when you want to investigate five factors or more and if you need to plan a lot of runs. But consider this: An example using the scenario of five parameters clearly shows that the number of runs required is even lower for a DoE and at the same time will lead to higher power values for the main effects and quadratic effects:

6. Set the Right Control Strategy for Individual Unit Operations

Setting the control strategy is the goal of a PCS study. This can be done either for each unit operation separately or in a holistic fashion. For a better understanding, think about a chain of workers in a manufacturing process. If one worker makes a mistake, others might be able to compensate. Herein, setting a control strategy for each worker individually does not accurately control for the overall failure rate. 

The same applies if we think about a chain of unit operations that might be able to contribute to the clearance of impurities. State of the art procedures use established models for individual unit operations to set a control strategy that might be much too conservative.

7. Establish a Holistic Control Strategy

If you want to set the control strategy based on the patients’ needs, you must meet overall drug substance specifications. This requires the understanding of how single PPs impact on changing CQAs in drug substance.

As a result of a parameter sensitivity analysis, out of specification (OOS) chances can be estimated as a function of PPs of any unit operation. A risk-based decision criteria (e.g., a change to 5% OOS) can be used to determine the control limits for any PP. 

As a result of that holistic approach, the control strategy stays rigid where this is required to reach drug substance specifications. But it is as wide as possible to obtain manufacturing flexibility.

Executive Summary

A successful PCS study is key to reduce time-to-market of any biopharmaceutical product. This can be achieved by the unique workflow established by the experienced consultants from Körber:

  1. A process validation master plan ensures that scope, deliverables, and timelines are aligned between all stakeholders of a PCS.
  2. Statistical occurrence analysis and new risk rating scales reduce subjectivity during risk assessments.
  3. Innovative visualization techniques ensure fast and precise identification of critical unit operations to reach the required Quality Target Product Profile. Understanding how impurities are created and cleared in your process helps to plan the right type of experiments, i.e., spiking studies vs. DoE studies.
  4. Statistical equivalence testing ensures not to overlook practically relevant differences between scales. These offsets need to be considered for predictions at manufacturing scale.
  5. Cutting edge optimal experimental designs enable to identify main and interaction effects of PPs onto CQAs with a minimum number of experiments.
  6. Establishment of statistically and practically relevant models enables the establishment of integrated process models. 
  7. Only holistic definition of the control strategy using integrated process modeling ensures meeting drug substance specifications and thereby ensures patient’s safety.

Planning, analysis, and execution of necessary experiments is at the center of the PCS work. Statistical tools such as data assisted risk assessment, DoE planning and integrated process modeling can facilitate this work and ensure the right focus and reduction of experimental effort, setting of feasible control strategies for manufacturers and finally timely market entry. 

With PAS-X CMC Consulting, Körber assists with in-depth knowledge from its combined experience in data science and pharmaceutical production processes. Our consultants have 8+ years of experience in consulting and statistical services for process characterization and validation and have successfully contributed to bringing 20+ products to the market. 

Get into contact with our experts on any related questions or for detailed information on what we can provide.

Contact us

Kommentare

Keine Kommentare

Kommentar schreiben

* Diese Felder sind erforderlich

nach oben
nach oben